hIL12B/hIL23A/hTL1A(3)

Fig.1 Body weight and body weight change among time during study. Body weight and body weight change in anti-IL23 treated imiquimod (IMQ)-induced psoriasis in HO hTL1A/hIL23A/hIL12B mice (n=3-4 /group, 6weeks, male). IMQ treatment induced body weight loss in male hTL1A/hIL23A/hIL12B mice. Risankizumab treatment didn’t alleviate the weight loss.

Fig.2 Psoriasis evaluation among time during study. In vivo efficacy evaluation of anti-IL23 in imiquimod (IMQ)-induced psoriasis in hTL1A/hIL23A/hIL12B mice (n=3-4 /group, 6weeks, male). IMQ treatment successfully induced psoriasis-like skin inflammation in female HO hTL1A/hIL23A/hIL12B mice, characterized by increased elevated PASI scores (including erythema and scaling) over the 7-day observation period. Notably, Risankizumab alleviated IMQ-induced psoriasis.

Fig.3 H&E staining of psoriatic skin lesions in IMQ-induced mice. Representative H&E staining images of skin from the (A) control, (B) IMQ + vehicle, and (C) IMQ + Risankizumab groups. Scale bar = 500 µm. (D) Baker score based on HE pathology images (n=3/group, 6 weeks old). IMQ treatment induced significant psoriasis-like skin thickening and histopathological features, including parakeratosis, spongiosis, dilated capillaries, and lymphocytic infiltration, as observed in the IMQ-treated groups. Risankizumab treatment slightly alleviated these psoriatic symptoms and reduced epidermal thickness, demonstrating its therapeutic effect in this IMQ-induced psoriasis model.